Cancer/testis antigens and urological malignancies
- 19 June 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 9 (7) , 386-396
Abstract
In this Review, Kulkarni and colleagues evaluate the available literature regarding the utility of cancer/testis antigens as biomarkers and therapeutic tools for patients with prostate, bladder, renal cell, and testicular germ cell tumours. Cancer/testis antigens (CTAs) are a group of tumour-associated antigens (TAAs) that display normal expression in the adult testis—an immune-privileged organ—but aberrant expression in several types of cancers, particularly in advanced cancers with stem cell-like characteristics. There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma. The resulting data have not only highlighted a role for CTAs in tumorigenesis, but have also underscored the translational potential of these antigens for detecting and treating many types of cancers. Studies that have investigated the use of CTAs for the clinical management of urological malignancies indicate that these TAAs have potential roles as novel biomarkers, with increased specificity and sensitivity compared to those currently used in the clinic, and therapeutic targets for cancer immunotherapy. Increasing evidence supports the utilization of these promising tools for urological indications.Keywords
This publication has 108 references indexed in Scilit:
- Global Trends in Testicular Cancer Incidence and MortalityEuropean Urology, 2011
- A majority of the cancer/testis antigens are intrinsically disordered proteinsJournal of Cellular Biochemistry, 2011
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- The biology of cancer testis antigens: Putative function, regulation and therapeutic potentialMolecular Oncology, 2011
- LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profilingBritish Journal of Cancer, 2010
- A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription ProgramsCell, 2010
- Intrinsic Protein Disorder and Interaction Promiscuity Are Widely Associated with Dosage SensitivityCell, 2009
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumorsNature Genetics, 2008
- Generation of germline-competent induced pluripotent stem cellsNature, 2007
- Testicular germ-cell tumours in a broader perspectiveNature Reviews Cancer, 2005